Recce Pharmaceuticals Limited (ASX:RCE)
Recce Pharmaceuticals Ltd (ASX:RCE) is developing a New Class of Synthetic Anti-Infectives designed to address the urgent global health problems of antibiotic resistant superbugs and emerging viral pathogens.
Recces anti-infective pipeline includes three patented, broad-spectrum, synthetic polymer anti-infectives:
- RECCE 327 as an intravenous and topical therapy that is being developed for the treatment of serious and potentially life-threatening infections due to Gram-positive and Gram-negative bacteria including their superbug forms;
- RECCE 435 as an orally administered therapy for bacterial infections; and
- RECCE 529 for viral infections.
Through their multi-layered mechanisms of action, Recces anti-infectives have the potential to overcome the hypercellular mutation of bacteria and viruses the challenge of all existing antibiotics to date.
The FDA has awarded RECCE 327 Qualified Infectious Disease Product designation under the Generating Antibiotic Initiatives Now (GAIN) Act labelling it for Fast Track Designation, plus 10 years of market exclusivity post approval. Further to this designation, RECCE 327 has been included on The Pew Charitable Trusts Global New Antibiotics in Development Pipeline as the worlds only synthetic polymer and sepsis drug candidate in development.
RECCE 327 is not yet market approved for use in humans with further clinical testing required to fully evaluate safety and efficacy.
Recce wholly owns its automated manufacturing, which is supporting present clinical trials. Recces anti-infective pipeline seeks to exploit the unique capabilities of its technologies targeting synergistic, unmet medical needs.